Clinical trials attempting to modify PRRs activities in AD patients are under course in relation to RAGE, TREM2, and NLRP3, whereas a trial about CD36 gave inconclusive results for lack of evidence (Table 4). Here, NLRP3 is linked to Alzheimer disease.